Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE Combined With Low-Dose Bevacizumab Plus Atezolizumab for Unresectable HCC
NCT07281664Phase 2Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of bevacizumab, atezolizumab in hepatocellular carcinoma (HCC), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
bevacizumabatezolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07281664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281664.